Cullinan Therapeutics, Inc. CGEM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $188.07M+0.4% | $187.4M+1.3% | $184.95M+3.6% | $178.49M+16.1% | $153.72M+7.6% | ||
| $52.28M-3.6% | $54.25M-4.0% | $56.49M+0.5% | $56.21M+1.8% | $55.21M+2.2% | ||
| $240.35M-0.5% | $241.65M+0.1% | $241.44M+2.9% | $234.7M+12.3% | $208.93M+6.1% | ||
| -$240.35M+0.5% | -$241.65M-0.1% | -$241.44M-2.9% | -$234.7M-12.3% | -$208.93M-6.1% | ||
| -$420K+5.2% | -$443K-18.4% | -$374K-5.4% | -$355K-44.3% | -$246K-20.0% | ||
| -$221.04M-0.5% | -$219.88M-1.4% | -$216.81M-4.9% | -$206.76M-15.7% | -$178.74M-6.8% | ||
| —— | —— | —— | —— | —— | ||
| -$240.04M+0.5% | -$241.34M-0.1% | -$241.13M-2.9% | -$234.39M-12.4% | -$208.62M-6.1% | ||
| -$240.35M+0.5% | -$241.65M-0.1% | -$241.44M-2.9% | -$234.7M-12.3% | -$208.93M-6.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Cullinan Therapeutics, Inc. profitable?
- Cullinan Therapeutics, Inc. is not currently profitable: it reported a net loss of $221.0M over the trailing twelve months, a -346.1% net margin.
- What is Cullinan Therapeutics, Inc.'s earnings per share?
- Cullinan Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.84.
- Where does Cullinan Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.